Dr. Landgren is Chief of the Myeloma Division, Director of Sylvester Myeloma Research Institute, and Leader of the Experimental Therapeutics Program at Sylvester Comprehensive Cancer Center at University of Miami. Previously, he served as the Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center in New York City. Over the past several years, he has designed and conducted a series of studies to define biological mechanisms of transformation from myeloma precursor disease (monoclonal gammopathy of undetermined significance [MGUS] and smoldering myeloma) to multiple myeloma. His work has resulted in the identification of myeloma genomic defining events, which sets the stage for optimized treatment initiation of patients with early myeloma, and identification of individuals who can be monitored without therapy. Dr. Landgren has launched several early-interventional clinical trials designed to offer rapid and deep responses. Beyond traditional clinical criteria for complete remission, he has developed strategies to define minimal residual disease (MRD) detection post-therapy using cell-, molecular-, and imaging-based methods. Dr. Landgren has a strong interest in early drug development and he has served as the principal investigator for a large number of clinical trials with novel drugs and with integration of MRD testing. He is a frequently invited speaker at national and international meetings. He serves on several advisory boards and he is a frequent grant reviewer. He has published more than 400 peer reviewed publications including many papers in high impact journals such as New England Journal of Medicine, Nature Medicine, Nature Communications, Lancet, JAMA, and Blood.